| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
A high VWF:Ag/ADAMTS13:AC ratio in acute-Kawasaki disease (KD) persisted after primary treatment in non-responders, and unbalanced substrate-to-enzyme ratio appeared to associate with vascular endothelial damage. Analysis of existing mode of ADAMTS13 may help to clarify pathogenesis of IVIG resistance in acute-KD.
Acute KD in children was characterized by PTF (platelet thrombus formation under flow conditions)'s early onset and weak stability. Though the current antiplatelet therapy of acute KD in 1week and 1month by aspirin or flurbiprofen effectively suppresses platelet activation, antiplatelet drugs, such as platelet GP IIb/IIIa receptor inhibitor, might be more reasonable for acute KD due to inhibiting the PTF onset.
|
